Emerging Biotech
Achieve Launch Excellence
with Confidence and Speed
Getting your innovation to patients, faster.
50%
of all product launches will be by pre-commercial companies by 2025
39%
of first-time launchers achieve their sales forecast
70%
of biotechs launch their first brands with Veeva
35%
of revenue from international drug launches come from outside the U.S.
eBook
Pre-commercial guide to launch excellence
Identify the right mix of go-to-market plans and operational capabilities in this pre-commercial roadmap for biopharmas.
“We stood up a full commercial launch in about 75 days. Having an integrated suite of commercial solutions helped streamline the entire process.”
Bob Acropolis
Executive Director, Commercial Operations and Analytics of Rare Disease, ANI Pharmaceuticals
“Veeva’s Commercial solutions enable Idorsia’s sales, medical, and marketing teams to align their engagement and content strategy for a more customer-centric and coordinated experience.”
Bas Van de Kamp
Director Medical Affairs Systems, Idorsia Pharmaceuticals
“With Veeva as our trusted partner, we accelerated launch readiness and equipped new sales, medical, and marketing teams with the digital tools they need.”
Christopher Mutz
Chief Commercial Officer & Head of Rare Disease, ANI Pharmaceuticals
Our Customers
Succeed in your launch strategy, from planning to efficient commercial execution
Launch solutions
for emerging biotech
Learn why hundreds of pre-commerial companies rely on Veeva to plan and execute their launch.
